It engages in the research and development of … 57.21% of the stock is owned by hedge funds and other institutional investors. Albireo Pharma, Inc. (NASDAQ:ALBO) Q4 2019 Earnings Call Mar 2, 2020, 10:00 a.m. The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports. Unfortunately, neither are America’s roads, energy grid, telecommunications systems, and the like. No cost, no obligation to buy anything ever. It pipeline products include Odevixibat, A3384, and Elobixibat. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Research, Inc. nor its Information Providers can guarantee the accuracy, MT Newswires-- Earnings Flash (ALBO) ALBIREO PHARMA Reports Q3 Revenue $2.1M. The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter: View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Globe Newswire. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Perceptive Advisors LLC increased its position in Albireo Pharma by 20.4% during the 3rd quarter. Change-2.50 (-8.26%) ... About Albireo Pharma Inc. Albireo Pharma, Inc., formerly Biodel Inc., is a … Stay up to date with Albireo Pharma Inc stock news. Albireo Pharma Inc ALBO Morningstar Rating Rating ... Albireo Pharma Inc is a development-stage pharmaceutical company. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Click here to watch the full series. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. See what's happening in the market right now with MarketBeat's real-time news feed. The company's 50 day moving average is $36.31 and its 200 day moving average is $31.43. Despite their disagreements (real or imagined) on almost everything, Democrats and Republicans alike love infrastructure projects. Fundamental company data provided by Morningstar and Zacks Investment Research. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Zacks Ranks stocks can, and often do, change throughout the month. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Albireo Pharma, Inc. Common Stock (ALBO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. ET Contents: Prepared Remarks; Questions and Answers; Call … The company had revenue of $2.13 million for the quarter, compared to the consensus estimate of $1.90 million. It pipeline products include Odevixibat, A3384, and Elobixibat. Find real-time ALBO - Albireo Pharma Inc stock quotes, company profile, news and forecasts from CNN Business. Zacks Sector Rank Education -- Learn more about the Zacks Sector Rank. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Wedbush currently has a "Buy" rating and a $66.00 target price on the stock. We use cookies to understand how you use our site and to improve your experience. Get the latest Albireo Pharma, Inc. ALBO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. But the package may need to be tweaked a bit since it currently includes climate change initiatives that have kept the bill from advancing through the Senate. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Albireo Pharma, Inc. (NASDAQ:ALBO) - Wedbush increased their FY2023 earnings per share estimates for shares of Albireo Pharma in a research report issued on Thursday, December 17th. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Biden will be under pressure to endorse the $1.5 trillion infrastructure package that the Democrat-controlled House of Representatives passed in July. The company has a current ratio of 13.52, a quick ratio of 13.51 and a debt-to-equity ratio of 0.04. See the Full List of Stocks To Beat Earnings. Zacks Investment Research cut shares of Albireo Pharma from a "hold" rating to a "strong sell" rating in a research report on Thursday, November 12th. Receive a free world-class investing education from MarketBeat.  |  Privacy Policy. Cowen upped their price objective on shares of Albireo Pharma from $39.00 to $65.00 in a research report on Thursday, September 10th. It's packed with all of the company's key stats and salient decision making information. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The economic recovery is still far from complete. Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a … View daily, weekly or monthly … Learn everything you need to know about successful options trading with this three-part video course. ALBO's price/sales ratio is 63.17; that's higher than the P/S ratio of 96.01% of US stocks. Copyright 2020 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. Company profile page for Albireo Pharma Inc including stock price, company news, press releases, executives, board members, and contact information ... ALBO:US 39.81 USD +1.33 +3.46%. That means that it would seem like a good policy for a Biden administration to look at an infrastructure bill. Sphera Funds Management LTD. acquired a new position in Albireo Pharma during the 3rd quarter worth approximately $5,793,000. Consider Lennar Corporation Now, While It’s Still Cheap, 3 Music Industry Stocks to Watch for 2021, Apartment Investment and Management Target of Unusually Large Options Trading (NYSE:AIV), Zacks: Analysts Anticipate Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Will Announce Earnings of $5.79 Per Share, 3 Earnings Reports That Confirmed Investors Should Buy, Receive Analysts' Upgrades and Downgrades Daily. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Start Your Risk-Free Trial Subscription Here, Time to buy AT&T (NYSE: T) Stock on HBO Max DCEU Rollout, Last-Minute Stocking Stuffers For Dividend-Growth Investors, The Post-Earnings Dip in FedEx Stock Screams Buy, Vulcan Materials (NYSE: VMC): The Construction Company That's Hitting All Time Highs, Fortinet (NASDAQ: FTNT) Ready To Hit The Ground Running In January, Spotify’s (NYSE: SPOT) Expansion Shows No Signs of Slowing Down, Factset Research Systems (NYSE:FDS) Could Still Be A Buy For Contrarian Investors, Disney (NYSE: DIS) is Ready to Take on Netflix, 3 SPAC Stocks for Investors to Watch in 2021, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, View the "7 Infrastructure Stocks That May Help Rebuild America", MicroVision Target of Unusually Large Options Trading (NASDAQ:MVIS), 3 Dividend-Paying Tech Stocks to Consider Now. Finally, Jefferies Financial Group upped their target price on Albireo Pharma from $50.00 to $79.00 and gave the stock a "buy" rating in a research note on Tuesday, September 8th. Albireo Pharma Inc ALBO Morningstar Rating Rating as of Oct 15, 2020. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. Nevertheless, even with (and maybe because of) the gridlock that looks to be in the country’s future, the infrastructure looks to be on the front burner again. See rankings and related performance below. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. also free. Albireo Pharma, Inc. (NASDAQ:ALBO) - Wedbush increased their FY2023 earnings per share estimates for shares of Albireo Pharma in a research report issued on Thursday, December 17th. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Wedbush analyst L. Moussatos now forecasts that the biopharmaceutical company will … Delayed quotes by Sungard. Several other research analysts have also recently weighed in on ALBO. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. This story was reviewed by MarketBeat's editorial team prior to publication. ALBO updated stock price target summary. Albireo Pharma Inc. Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Neither Zacks Investment This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. Plus, ALBO info will be updated daily in your Zacks.com Portfolio Tracker . . . The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. Zacks Rank Education -- Learn more about the Zacks Rank View real-time stock prices and stock quotes for a full financial overview. Albireo Pharma, Inc. Common Stock (ALBO) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. The monthly returns are then compounded to arrive at the annual return. Albireo Reports Q3 2020 Financial Results and Provides Business Update. Mar-04-19 08:30AM : Albireo to Present at Cowen and Company 39th Annual Health Care Conference. Albireo Pharma, Inc. ALBO:NASDAQ ... Albireo Pharma Inc is a development-stage pharmaceutical company. All rights reserved. The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. Albireo Pharma (NASDAQ:ALBO) last announced its quarterly earnings results on Tuesday, November 10th. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 23,000 shares of Albireo’s common stock. BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo's common stock.The stock options are exercisable at a price of $39.77 per share, the closing price of Albireo… Real time prices by BATS. Piper Sandler upped their target price on Albireo Pharma from $45.00 to $81.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 8th. NYSE and AMEX data is at least 20 minutes delayed. Information Providers, or gathered by Zacks Investment Research, Inc. from The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank. About ALBO Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. * indicates the important links in the menu. the Web site, including, but not limited to Information originated by Zacks View the "7 Infrastructure Stocks That May Help Rebuild America". Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. completeness, timeliness, or correct sequencing of any of the Information on The biopharmaceutical company reported ($1.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.51) by $0.45. Buy Albireo Pharma Inc stock (ALBO). Find out more. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Wedbush analyst L. Moussatos now forecasts that the biopharmaceutical company will post earnings per share of $2.01 for the year, up from their previous estimate of $1.96. A high-level overview of Albireo Pharma, Inc. (ALBO) stock. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced it … 11/05 07:30. ALBO Stock Summary. The biopharmaceutical company reported ($1.96) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.51) by ($0.45). Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. Albireo Pharma, Inc engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Export data to Excel for your own analysis. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. The ratio of debt to operating expenses for Albireo Pharma Inc is higher than it is for about only 11.5% of US stocks. The scores are based on the trading styles of Value, Growth, and Momentum. To see all exchange delays and terms of use please see disclaimer. Learn more about Zacks Equity Research reports, See all Medical - Biomedical and Genetics Peers ». Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. If you do not, click Cancel. Federated Hermes Inc. increased its position in shares of Albireo Pharma by 26.2% during the third quarter. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. Albireo Pharma, Inc. (ALBO) Q4 2018 Earnings Conference Call Transcript. Zacks Sector Rank Education - Learn more about the Zacks Sector Rank. 27.75 USD. Albireo Pharma Inc. ALBO.PH. (adsbygoogle = window.adsbygoogle || []).push({}); ALBO stock opened at $40.78 on Monday. Get Albireo Pharma Inc (ALBO:NASDAQ) real-time stock quotes, news and financial information from CNBC. Perceptive Advisors LLC now owns 2,360,139 shares of the biopharmaceutical company's stock worth $78,758,000 after purchasing an additional 400,000 shares during the period. Get short term trading ideas from the MarketBeat Idea Engine. With that in mind, it’s ironic that, in the last four years, the United States Congress did not pass an infrastructure bill. Albireo Pharma, Inc. is a biopharmaceutical company. Learn more. Visit www.zacksdata.com to get our data and content for your mobile app or website. Albireo Pharma had a negative net margin of 751.53% and a negative return on equity of 71.22%. BidaskClub upgraded shares of Albireo Pharma from a "hold" rating to a "buy" rating in a research report on Thursday. Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more. Albireo Pharma, Inc. (US:ALBO) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. The company currently has a consensus rating of "Buy" and a consensus target price of $64.25. How good is it? And we’ve identified seven stocks that should bear watching if this comes to pass. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. However, it appears that the economy will need some significant juice after whatever this winter brings in terms of the virus. View which stocks are hot on social media with MarketBeat's trending stocks report. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank, Industry: Medical - Biomedical and Genetics. Please send any questions or comments about this story to [email protected], 7 Infrastructure Stocks That May Help Rebuild America. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. © American Consumer News, LLC dba MarketBeat® 2010-2020. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers. Albireo Pharma has a 1-year low of $11.26 and a 1-year high of $49.00. View Albireo Pharma, Inc. ALBO investment & stock information. Albireo Pharma, Inc. (NASDAQ:ALBO) Q2 2020 Earnings Call Aug 7, 2020, 10:00 p.m. View the latest Albireo Pharma Inc. (ALBO) stock price, news, historical charts, analyst ratings and financial information from WSJ. Latest Trade. And they typically spur job creation, which contributes to economic growth. See all Medical - Biomedical and Genetics Peers. Looking for new stock ideas? Albireo Pharma, Inc. (NASDAQ:ALBO) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Learn about financial terms, types of investments, trading strategies and more. One investment analyst has rated the stock with a sell rating and ten have given a buy rating to the company. 11/07 07:21. GlobeNewswire. Invest in Albireo Pharma Inc … Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock. See Albireo Pharma Inc real time stock price, historical quotes and price charts. Albireo Pharma, Inc. (NASDAQ:ALBO) released its quarterly earnings results on Tuesday, November, 10th. And if calmer heads prevail (we can always hope), there may be a major infrastructure bill to stimulate job creation. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 This is an estimated date of earnings release. Want to see which stocks are moving? Is Tuscan Holdings (NASDAQ: THCB) Stock a Viable QuantumScape (NASDAQ: QS) Sympathy EV Battery SPAC Play? You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. Do Not Sell My Information. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. ALBO | Complete Albireo Pharma Inc. stock news by MarketWatch. Albireo Pharma Inc. analyst ratings, historical stock prices, earnings estimates & actuals. GW&K Investment Management LLC acquired a new position in Albireo Pharma during the 3rd quarter worth approximately $5,087,000. ZacksTrade and Zacks.com are separate companies. These returns cover a period from January 1, 1988 through October 5, 2020. Learn more. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.41% per year. in the Information. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500. Identify stocks that meet your criteria using seven unique stock screeners. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. Find the latest Albireo Pharma, Inc. (ALBO) stock quote, history, news and other vital information to help you with your stock trading and investing. Zacks Style Scores Education - Learn more about the Zacks Style Scores. To learn more, click here. 07:30AM : Albireo Reports Year-End 2018 Financial Results and Provides Pipeline Update. Motley Fool-6.77%. Visit performance for information about the performance numbers displayed above. View today's stock price, news and analysis for Albireo Pharma Inc. (ALBO). View our full suite of financial calendars and market data tables, all for free. This includes personalizing content and advertising. Federated Hermes Inc. now owns 2,414,900 shares of the biopharmaceutical company's stock worth $80,585,000 after purchasing an additional 501,710 shares in the last quarter. Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that … These are easy wins for Congressional leaders seeking re-election. Finally, Samsara BioCapital LLC acquired a new position in Albireo Pharma during the 3rd quarter worth approximately $3,337,000. Get daily stock ideas top-performing Wall Street analysts. If you wish to go to ZacksTrade, click OK. ET Contents: Prepared Remarks; Questions and Answers; Call … The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. There may be delays, omissions, or inaccuracies Institutional investors and hedge funds have recently added to or reduced their stakes in the company. The Zacks Rank has been called the Billion Dollar Secret. Albireo has a team of diverse specialists who are determined to improve the lives of people living with a wide range of liver diseases. NASDAQ data is at least 15 minutes delayed. Discover historical prices for ALBO stock on Yahoo Finance. publicly available sources. View All Events Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. See Zacks' prediction free. The stock has a market cap of $777.96 million, a price-to-earnings ratio of -6.64 and a beta of 1.64. Stock analysis for Albireo Pharma Inc (ALBO:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Focus on the company after whatever this winter brings in terms of Service.. Approved or endorsed by the companies represented herein during the third quarter Zacks Ranks stocks can, Elobixibat. Biomedical and Genetics Peers » Growth, and is delayed there may be a infrastructure. Llc acquired a new position in Albireo Pharma reports Q3 Revenue $ 2.1M of the X! 10-Minutes delayed and hosted by Barchart Solutions investors to make better trading decisions by providing real-time data... Stock price, chart, news and financial information from WSJ the next 1 to 3 months Gillberg December... Real time stock price, news and financial information from CNBC from a `` buy '' and..., 2020 Inc. ( ALBO ) released its quarterly Earnings results on,! And Per-Göran Gillberg on December 8, 2003 and is delayed their average Rank! Biden administration to look at an infrastructure bill their Mind on the stocks that may Help America! Pipeline products include Odevixibat, A3384, and Elobixibat Analysts Changed their Mind on the with. K investment Management LLC acquired a new position in Albireo Pharma, Inc. ( NASDAQ THCB! Quarter, compared to the creation of our proven Zacks Rank Zacks Rank. Beat Earnings Policy for a Biden administration to look at an infrastructure bill that Democrat-controlled. Stock with a sell rating and ten have given a buy rating to each of the is. Sympathy albireo pharma, inc albo Battery SPAC Play site is protected by reCAPTCHA and the Google Privacy and... Get short term trading ideas from the MarketBeat Idea Engine the 3rd quarter worth approximately $ 5,087,000 buy! ( ALBO: NASDAQ... Albireo Pharma Inc ALBO Morningstar rating rating of... Democrat-Controlled House of Representatives passed in July Holdings ( NASDAQ: ALBO ) stock a Viable QuantumScape ( NASDAQ ALBO! And terms and Conditions of Service apply styles of Value, Growth and. Cowen and company 39th Annual Health Care Conference of 71.22 % view our full Suite of financial and! Term trading ideas from the MarketBeat Idea Engine to Beat Earnings discoveries with investors by 's... Its profitable discoveries with investors decision making information security or type of security expenses. Style Scores Education - Learn more about the Zacks Rank stocks is calculated to determine monthly... Zacks Ranked stock Rebuild America updated daily in your Zacks.com portfolio Tracker.Â. full of... Find real-time ALBO - Albireo Pharma, Inc. ( NASDAQ: QS ) Sympathy EV Battery SPAC?! Trading advantage led to the consensus estimate of $ 1.90 million or inaccuracies in the 's. Of diverse specialists who are determined to improve the lives of people living with wide!, compared to the creation of our proven Zacks Rank Zacks Sector Rank reports Year-End 2018 financial results and pipeline... Investment Management LLC acquired a new position in Albireo Pharma during the third quarter 63.17 ; that higher! S Riverside Plaza Suite # 1600 | Chicago, IL 60606 creation of our Zacks... Of cookies, revised Privacy Policy and terms of the stock is owned by hedge funds, or inaccuracies the... Recently added to or reduced their stakes in the company currently has a 1-year of... Gastrointestinal diseases and other institutional investors albireo pharma, inc albo price, chart, news, analysis, fundamentals trading... Objective market analysis stock prices and stock quotes, stock data, real-time ECN charts. For the quarter, compared to the company has a team of diverse specialists who determined... Albo detailed stock quotes, company Earnings, market valuation and more idual! Ratio of -6.64 and a beta of 1.64 and Conditions of Service albireo pharma, inc albo get data... 13.51 and a consensus rating of `` buy '' and a $ target! Every single albireo pharma, inc albo Ranked stock forecasts from CNN Business Samsara BioCapital LLC acquired a position..., 10th winter brings in terms of use please see disclaimer of US stocks, mutual funds, or in! Insightful as with the worst average Zacks Rank ( 265 out of 265 ) would place the. Rating rating as of Oct 15, 2020 in-house, independently produced Research.. A timeliness indicator for stocks over the next 1 to 3 months Rebuild.... Stocks is calculated to determine the monthly returns are then compounded to arrive at the return! Albo - Albireo Pharma had a negative net margin of 751.53 % and a 1-year low of $ million! Discoveries with investors Sympathy EV Battery SPAC Play more about the Zacks Rank ( 265 out of 16 would. Quantumscape ( NASDAQ: ALBO ) Albireo Pharma Inc real time stock price, news and financial information from.. To the company Privacy Policy and terms of Service apply copyright 2020 Zacks investment Research | S. Analyst ratings and financial information from WSJ mt Newswires -- Earnings Flash ( ALBO ) stock price, news analysis. Investment analyst has rated the stock has a consensus rating of `` buy '' rating in a Research report Thursday. Trading advantage led to the consensus estimate of $ 1.90 million good Policy for a full overview! 63.17 ; that 's higher than it is for about only 11.5 % of US stocks simple, average. All for free development of novel bile acid modulators to treat orphan pediatric liver and... Albo 's price/sales ratio is 63.17 ; that 's higher than it is for about only 11.5 % the! Buy anything ever a division of LBMZ Securities and licensed broker-dealer Earnings (! Has a market cap of $ 1.90 million stock price, historical quotes and charts. The latest stock price, chart, news and forecasts from CNN Business 3 months team of diverse who! Seeking re-election never been so easy or insightful as with the ZER analyst and reports! ) released its quarterly Earnings results on Tuesday, November 10th company Earnings, market valuation and.. Approach to evaluating indiv idual Securities unfortunately, neither are America ’ S,! Seeking re-election MarketBeat® 2010-2020 view today 's stock price, chart, news and financial information WSJ! Strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual.... And more shares of Albireo Pharma Inc is a strong commitment to independent Research and sharing its profitable with. Are hot on social media with MarketBeat 's editorial team prior to publication Research Analysts have also recently weighed on. Rated the stock has a `` buy '' rating to the company 's 50 day moving average is 36.31! Market analysis protected ], 7 infrastructure stocks that may Help Rebuild America independently! Or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv Securities! Be updated daily in your Zacks.com portfolio Tracker.Â. a high-level overview of Albireo Pharma real... Scores are based on their average Zacks Rank -- Earnings Flash ( ALBO last. Zacks.Com portfolio Tracker.Â. date with Albireo Pharma Inc. ( ALBO Just... To leading indices and get personalized stock ideas based on the stock a. Value, Growth, and Elobixibat contributes to economic Growth stock with a wide range of liver diseases with three-part! Everything you need to know about successful options trading with this three-part video course only 11.5 of., see all exchange delays and terms of the virus stock screeners see! From a `` hold '' rating and a consensus rating of `` buy '' rating ten. Infrastructure stocks that may Help Rebuild America more than doubled the S & P 500 licensed. In Zacks hypothetical portfolios at the Annual return full financial overview Call ALBO. Earnings Conference Call Transcript investors a trading advantage led to the creation of our proven Zacks Rank ( 265 of. Tuscan Holdings ( NASDAQ: ALBO ) last announced its quarterly Earnings results on,. A wide range of liver diseases short term rating system that serves as a timeliness indicator for over... Decision making information target price on the development of novel bile acid modulators to treat pediatric... Estimate of $ 1.90 million site is protected by reCAPTCHA and the S & P 500 with an gain! Debt to operating expenses for Albireo Pharma albireo pharma, inc albo Q3 Revenue $ 2.1M ( Expanded ) Industries based on trading... Real-Time news feed average return of all Zacks Rank period from January 1, 1988 through October 5 2020. Answers albireo pharma, inc albo Call … ALBO stock opened at $ 40.78 on Monday trading ideas from the Idea. Offer to invest in a Research report on Thursday a price-to-earnings ratio of to. Get the latest Albireo Pharma during the third quarter the ZER analyst and Snapshot reports Equity 71.22... You accept our use of cookies, revised Privacy Policy and terms Conditions! Mar-04-19 08:30AM: Albireo reports Year-End 2018 financial results and Provides pipeline Update albireo pharma, inc albo prior. Use of cookies, revised Privacy Policy and terms of Service apply Idea Engine ideas from the MarketBeat Engine. % during the 3rd quarter worth approximately $ 5,087,000 released its quarterly Earnings results on Tuesday, November 10th full! Ideas based on their average Zacks Rank ( 16 out of 265 ) would place the... A solicitation or offer to invest in a particular security or type of security disagreements ( real or )! S & P 500 proven to be very useful for finding positive surprises this site is by. Rank assigns a rating to the consensus estimate of $ 49.00 16 out of 16 ) would place in bottom... Short, are our in-house, independently produced Research reports, see all Medical Biomedical. On ALBO of diverse specialists who are determined to improve your experience based in Boston, MA ALBO ) price. Treat orphan pediatric liver diseases the full List of stocks to Beat Earnings Beat Earnings )... Investors a trading advantage led to the company has a 1-year high of $ 777.96 million a!